- Home
- CRSP vs AXSM Comparison
CRSP vs AXSM Comparison
Compare CRSP & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- AXSM
- Stock Information
- Founded
- CRSP 2013
- AXSM 2012
- Country
- CRSP Switzerland
- AXSM United States
- Employees
- CRSP N/A
- AXSM N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- CRSP Health Care
- AXSM Health Care
- Exchange
- CRSP Nasdaq
- AXSM Nasdaq
- Market Cap
- CRSP 5.6B
- AXSM 5.9B
- IPO Year
- CRSP 2016
- AXSM 2015
- Fundamental
- Price
- CRSP $71.48
- AXSM $119.22
- Analyst Decision
- CRSP Buy
- AXSM Strong Buy
- Analyst Count
- CRSP 18
- AXSM 19
- Target Price
- CRSP $72.59
- AXSM $174.26
- AVG Volume (30 Days)
- CRSP 2.6M
- AXSM 472.6K
- Earning Date
- CRSP 11-04-2025
- AXSM 11-03-2025
- Dividend Yield
- CRSP N/A
- AXSM N/A
- EPS Growth
- CRSP N/A
- AXSM N/A
- EPS
- CRSP N/A
- AXSM N/A
- Revenue
- CRSP $38,050,000.00
- AXSM $495,033,000.00
- Revenue This Year
- CRSP N/A
- AXSM $63.62
- Revenue Next Year
- CRSP $388.50
- AXSM $55.72
- P/E Ratio
- CRSP N/A
- AXSM N/A
- Revenue Growth
- CRSP N/A
- AXSM 69.83
- 52 Week Low
- CRSP $30.04
- AXSM $75.56
- 52 Week High
- CRSP $73.95
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- CRSP 66.62
- AXSM 51.72
- Support Level
- CRSP $67.41
- AXSM $117.60
- Resistance Level
- CRSP $73.95
- AXSM $122.14
- Average True Range (ATR)
- CRSP 3.46
- AXSM 3.15
- MACD
- CRSP 0.87
- AXSM -0.29
- Stochastic Oscillator
- CRSP 76.46
- AXSM 35.03
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.